Lipomedix
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box, Jerusalem, Jerusalem, 39262, Isr...Phone Number
+972 25866177Website
www.lipomedix.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Lipomedix
Lipomedix, founded in 2011, is a clinical-stage pharmaceutical company focused on oncology research and development. The company specializes in developing innovative cancer therapies using a pegylated liposomal drug delivery platform. Their primary product, Promitil, is designed to overcome toxicity issues associated with traditional cancer treatments and has potential applications for various cancers, particularly those affecting the gastrointestinal tract. Lipomedix leverages advanced drug delivery technology to create more effective and safer cancer treatment options, building on established scientific foundations in liposomal drug development.Explore more
Popular SearchesLipoMedixLipoMedix Pharmaceutical IncLipomedix Pharmaceutical LtdLipomedix Pharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Show moreLipomedix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lipomedix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Lipomedix, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Lipomedix recently announced quarterly report
Product Launch: Get notified when Lipomedix launches new products
Check if Lipomedix has recently received funding, and reach out quickly before it becomes old news!
Check out if Lipomedix is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Lipomedix
Funding: Get notified immidiatlly once Lipomedix has new funding data
Click to see if Lipomedix had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Lipomedix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lipomedix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lipomedix.
Lipomedix Tech Stack
A closer look at the technologies used by Lipomedix
See more technologies
Lipomedix News & Media
LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®
JERUSALEM, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- LipoMedix, a clinical-stage, oncology-focused pharmaceutical company involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that its lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), a privately owned, specialty pharmaceutical company focused on the development, manufacturing, and commercializationLipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs
Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC) Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC)LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee
Jerusalem, Aug. 05, 2019 (GLOBE NEWSWIRE) -- LipoMedix Pharmaceuticals Ltd., a clinical and development-stage company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery, today announced the addition of Miranda J. Toledano and Praveen Tyle, Ph.D., to its board of directors. The company also announced the formation of an executive committee of the board to enhance governance and support the company’s development. Ms. Toledano and DLipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019
Givat Ram High-Tech Village, Jerusalem, March 29, 2019 (GLOBE NEWSWIRE) -- Lipomedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that the new clinical data of Promitil® in patients with metastatic colorectal cancer will be presented at the American Association for Cancer Research (AACR) annual meeting in Atlanta, Georgia.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lipomedix
Sign Up For FreeTo access detailed company insights
Lipomedix, founded in 2011, is a clinical-stage pharmaceutical company focused on oncology research and development. The company specializes in developing innovative cancer therapies using a pegylated liposomal drug delivery platform. Their primary product, Promitil, is designed to overcome toxicity issues associated with traditional cancer treatme... Read More
